Innova Captab Ltd (INNOVACAP) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039112,
    "name": "Innova Captab",
    "stock_name": "Innova Captab",
    "full_name": "Innova Captab Ltd",
    "name_url": "stocks-analysis/innova-captab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "720.85",
    "chg": 29.4,
    "chgp": "4.25%",
    "dir": 1,
    "prev_price": "691.45",
    "mcapval": "4,198.00 Cr",
    "mcap": "Small Cap",
    "scripcode": "544067",
    "symbol": "INNOVACAP",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0DUT01020",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "76.73 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/innova-captab-10039112-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Innova Captab Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/innova-captab-technical-momentum-shifts-amid-prolonged-downtrend-3740475",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/InnovaCaptab_technicaldot_3740475.png",
        "date": "2025-12-02 08:13:25",
        "description": "Innova Captab, a key player in the Pharmaceuticals & Biotechnology sector, is exhibiting a nuanced shift in its technical momentum as recent evaluation adjustments reflect a transition from bearish to mildly bearish trends. Despite a subdued price movement, the stock’s technical indicators present a complex picture that investors and analysts are closely monitoring amid broader market dynamics."
      },
      {
        "title": "How has been the historical performance of Innova Captab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-innova-captab-3739421",
        "imagepath": "",
        "date": "2025-12-01 23:42:18",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Growth</strong></p>\n<p>Over the fiscal years ending March 2023 to March 2025, Innova Captab’s net sales have shown a steady increase, rising from ₹926.38 crores in March 2023 to ₹1,243.68 crores in March 2025. This represents a compound growth trend reflecting the company’s expanding market presence and sales capabilities. Correspondingly, the total operating income mirrored this growth, with no other operating income reported during this period.</p>\n<p>The company’s operating profit before depreciation, interest, and tax (PBDIT) also improved significantly, climbing from ₹122.85 crores in March 2023 to ₹198.21 crores in March 2025. This increase was supported by a rising operating profit margin, which expanded from 12.27% to 14.97%, indicating enhanced operational efficie..."
      },
      {
        "title": "Innova Captab's Evaluation Metrics Revised Amidst Challenging Market Performance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/innova-captab-downgraded-to-strong-sell-amid-deteriorating-fundamentals-3735242",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/InnovaCaptab_mojoScore_3735242.png",
        "date": "2025-11-28 10:05:12",
        "description": "Innova Captab has experienced a revision in its evaluation metrics reflecting recent financial and technical developments. The pharmaceutical and biotechnology small-cap company’s assessment now signals a more cautious market outlook, influenced by its operational results and stock performance trends."
      },
      {
        "title": "Innova Captab Hits Intraday High with Strong Trading Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/innova-captab-hits-intraday-high-with-849-surge-on-25-nov-2025-3728142",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/InnovaCaptab_priceRelatedfactors_3728142.png",
        "date": "2025-11-25 09:43:01",
        "description": "Innova Captab recorded a notable surge today, touching an intraday high of Rs 791.25, reflecting a gain of 8.49% amid heightened volatility and active trading. This performance stands out despite the stock’s recent downward trend over the past two sessions."
      },
      {
        "title": "Why is Innova Captab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-innova-captab-fallingrising-3703595",
        "imagepath": "",
        "date": "2025-11-15 00:06:33",
        "description": "As of 14-Nov, Innova Captab Ltd's stock price is currently at 752.00, reflecting an increase of 22.05 (3.02%). The stock has shown a positive trend recently, gaining for the last two days with a total return of 6.15% during this period. Despite this short-term gain, the stock has underperformed over the longer term, with a 1-month return of -9.77% and a year-to-date return of -31.88%. The stock is trading at a discount compared to its peers, supported by a low Debt to EBITDA ratio of 1.40 times and a return on capital employed (ROCE) of 12.4. However, the company has faced challenges, including a significant decline in investor participation, as evidenced by a 42.52% drop in delivery volume against the 5-day average.\n\nBroader market context indicates that while Innova Captab has outperformed its sector by 2.65% today, it has lagged behind the benchmark Sensex, which has gained 1.62% over the past week. The ..."
      },
      {
        "title": "Why is Innova Captab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-innova-captab-fallingrising-3687425",
        "imagepath": "",
        "date": "2025-11-11 00:19:42",
        "description": "As of 10-Nov, Innova Captab Ltd's stock price is currently at Rs 738.40, reflecting a decline of Rs 29.35 or 3.82%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total drop of 10.6% during this period. It opened with a loss of 2.31% today and reached an intraday low of Rs 738.40. Over the past week, the stock has decreased by 9.04%, and its year-to-date performance shows a significant decline of 33.12%. Despite a strong ability to service debt and attractive valuations compared to peers, the stock's recent performance is negatively impacted by flat results in the latest quarter, including a decrease in profit after tax and consistent underperformance against benchmarks over the last three years.\n\nIn the broader market context, the Sensex has only declined by 0.53% over the past week, indicating that Innova Captab's performance is significantly worse ..."
      },
      {
        "title": "Are Innova Captab latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-innova-captab-latest-results-good-or-bad-3682504",
        "imagepath": "",
        "date": "2025-11-08 19:23:17",
        "description": "Innova Captab's latest financial results for the September 2025 quarter reveal a complex picture characterized by strong revenue growth juxtaposed with declining profitability. The company reported net sales of ₹380.38 crores, achieving a year-on-year increase of 19.54% and a quarter-on-quarter growth of 8.20%. This marks a record high for the company, indicating robust demand across its product segments.\n\nHowever, this top-line momentum is overshadowed by significant challenges on the bottom line. The net profit for the quarter fell to ₹29.67 crores, reflecting a decline of 15.23% year-on-year and a decrease of 4.35% from the previous quarter. The profit after tax (PAT) margin also contracted to 7.80%, down from 8.82% in the prior quarter, indicating a 102 basis points decline. This erosion of margins raises concerns about the company's ability to sustain profitability amid rising operational costs, includ..."
      },
      {
        "title": "Innova Captab Q2 FY26: Profit Decline Amid Revenue Growth Signals Margin Pressure",
        "link": "https://www.marketsmojo.com/news/result-analysis/innova-captab-q2-fy26-profit-decline-amid-revenue-growth-signals-margin-pressure-3680921",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/InnovaCaptab_quaterlyResult_3680921.png",
        "date": "2025-11-07 21:49:37",
        "description": "Innova Captab Limited, a small-cap pharmaceutical manufacturer with a market capitalisation of ₹4,589 crores, reported mixed quarterly results for Q2 FY26, with net profit declining 4.35% quarter-on-quarter to ₹29.67 crores despite revenue growth of 8.20%. The company's shares tumbled 4.65% on November 7, closing at ₹764.25, reflecting investor concerns over deteriorating profitability metrics and persistent margin compression that has plagued the company's recent performance."
      },
      {
        "title": "Is Innova Captab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-innova-captab-overvalued-or-undervalued-3678150",
        "imagepath": "",
        "date": "2025-11-07 08:13:08",
        "description": "As of 6 November 2025, Innova Captab has moved from a fair to attractive valuation grade, indicating a more favorable outlook. The company is currently considered undervalued. Key ratios include a PE ratio of 35.54, an EV to EBITDA of 24.91, and a PEG ratio of 0.99, which suggests that the stock is priced reasonably relative to its growth potential.\n\nIn comparison to its peers, Innova Captab's PE ratio is higher than Sun Pharma's 35.02 but lower than Divi's Lab's significantly high 79.09, indicating a competitive position within the industry. Additionally, while Cipla has a more attractive PE of 22.27, Innova Captab's PEG ratio of 0.99 suggests it offers better growth at its current price. Despite recent underperformance against the Sensex, with a year-to-date return of -26.98% compared to the Sensex's 6.62%, the valuation metrics support a bullish outlook for the stock moving forward...."
      }
    ],
    "total": 468,
    "sid": "10039112",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/innova-captab-10039112"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "02-Feb-2026",
      "details": "Transcript of the Investor/Analyst Earnings Call held on 27th January 2026: This is in continuation to our letter dated 27th January 2026 wherein we had informed regarding the audio link of the earnings call with analysts/investors for the quarter and nine months ended 31st December 2025.The transcript will be available on the Companys website.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "02-Feb-2026",
      "details": "Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Pursuant to Regulation 30 read with Schedule III (Part A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the officials of the Company will be attending the Investor Conference as per the details provided in intimation.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "02-Feb-2026",
      "details": "Transcript of the Investor/Analyst Earnings Call held on 27th January 2026: This is in continuation to our letter dated 27th January 2026 wherein we had informed regarding the audio link of the earnings call with analysts/investors for the quarter and nine months ended 31st December 2025.The transcript will be available on the Companys website.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Innova Captab Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:13:25

Innova Captab, a key player in the Pharmaceuticals & Biotechnology sector, is exhibiting a nuanced shift in its technical momentum as recent evaluation adjustments reflect a transition from bearish to mildly bearish trends. Despite a subdued price movement, the stock’s technical indicators present a complex picture that investors and analysts are closely monitoring amid broader market dynamics.

How has been the historical performance of Innova Captab?

2025-12-01 23:42:18

Revenue and Profit Growth Over the fiscal years ending March 2023 to March 2025, Innova Captab’s net sales have shown a steady increase, rising from ₹926.38 crores in March 2023 to ₹1,243.68 crores in March 2025. This represents a compound growth trend reflecting the company’s expanding market presence and sales capabilities. Correspondingly, the total operating income mirrored this growth, with no other operating income reported during this period. The company’s operating profit before depreciation, interest, and tax (PBDIT) also improved significantly, climbing from ₹122.85 crores in March 2023 to ₹198.21 crores in March 2025. This increase was supported by a rising operating profit margin, which expanded from 12.27% to 14.97%, indicating enhanced operational efficie...

Innova Captab's Evaluation Metrics Revised Amidst Challenging Market Performance

2025-11-28 10:05:12

Innova Captab has experienced a revision in its evaluation metrics reflecting recent financial and technical developments. The pharmaceutical and biotechnology small-cap company’s assessment now signals a more cautious market outlook, influenced by its operational results and stock performance trends.

Innova Captab Hits Intraday High with Strong Trading Momentum

2025-11-25 09:43:01

Innova Captab recorded a notable surge today, touching an intraday high of Rs 791.25, reflecting a gain of 8.49% amid heightened volatility and active trading. This performance stands out despite the stock’s recent downward trend over the past two sessions.

Why is Innova Captab falling/rising?

2025-11-15 00:06:33

As of 14-Nov, Innova Captab Ltd's stock price is currently at 752.00, reflecting an increase of 22.05 (3.02%). The stock has shown a positive trend recently, gaining for the last two days with a total return of 6.15% during this period. Despite this short-term gain, the stock has underperformed over the longer term, with a 1-month return of -9.77% and a year-to-date return of -31.88%. The stock is trading at a discount compared to its peers, supported by a low Debt to EBITDA ratio of 1.40 times and a return on capital employed (ROCE) of 12.4. However, the company has faced challenges, including a significant decline in investor participation, as evidenced by a 42.52% drop in delivery volume against the 5-day average. Broader market context indicates that while Innova Captab has outperformed its sector by 2.65% today, it has lagged behind the benchmark Sensex, which has gained 1.62% over the past week. The ...

Why is Innova Captab falling/rising?

2025-11-11 00:19:42

As of 10-Nov, Innova Captab Ltd's stock price is currently at Rs 738.40, reflecting a decline of Rs 29.35 or 3.82%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total drop of 10.6% during this period. It opened with a loss of 2.31% today and reached an intraday low of Rs 738.40. Over the past week, the stock has decreased by 9.04%, and its year-to-date performance shows a significant decline of 33.12%. Despite a strong ability to service debt and attractive valuations compared to peers, the stock's recent performance is negatively impacted by flat results in the latest quarter, including a decrease in profit after tax and consistent underperformance against benchmarks over the last three years. In the broader market context, the Sensex has only declined by 0.53% over the past week, indicating that Innova Captab's performance is significantly worse ...

Are Innova Captab latest results good or bad?

2025-11-08 19:23:17

Innova Captab's latest financial results for the September 2025 quarter reveal a complex picture characterized by strong revenue growth juxtaposed with declining profitability. The company reported net sales of ₹380.38 crores, achieving a year-on-year increase of 19.54% and a quarter-on-quarter growth of 8.20%. This marks a record high for the company, indicating robust demand across its product segments. However, this top-line momentum is overshadowed by significant challenges on the bottom line. The net profit for the quarter fell to ₹29.67 crores, reflecting a decline of 15.23% year-on-year and a decrease of 4.35% from the previous quarter. The profit after tax (PAT) margin also contracted to 7.80%, down from 8.82% in the prior quarter, indicating a 102 basis points decline. This erosion of margins raises concerns about the company's ability to sustain profitability amid rising operational costs, includ...

Innova Captab Q2 FY26: Profit Decline Amid Revenue Growth Signals Margin Pressure

2025-11-07 21:49:37

Innova Captab Limited, a small-cap pharmaceutical manufacturer with a market capitalisation of ₹4,589 crores, reported mixed quarterly results for Q2 FY26, with net profit declining 4.35% quarter-on-quarter to ₹29.67 crores despite revenue growth of 8.20%. The company's shares tumbled 4.65% on November 7, closing at ₹764.25, reflecting investor concerns over deteriorating profitability metrics and persistent margin compression that has plagued the company's recent performance.

Is Innova Captab overvalued or undervalued?

2025-11-07 08:13:08

As of 6 November 2025, Innova Captab has moved from a fair to attractive valuation grade, indicating a more favorable outlook. The company is currently considered undervalued. Key ratios include a PE ratio of 35.54, an EV to EBITDA of 24.91, and a PEG ratio of 0.99, which suggests that the stock is priced reasonably relative to its growth potential. In comparison to its peers, Innova Captab's PE ratio is higher than Sun Pharma's 35.02 but lower than Divi's Lab's significantly high 79.09, indicating a competitive position within the industry. Additionally, while Cipla has a more attractive PE of 22.27, Innova Captab's PEG ratio of 0.99 suggests it offers better growth at its current price. Despite recent underperformance against the Sensex, with a year-to-date return of -26.98% compared to the Sensex's 6.62%, the valuation metrics support a bullish outlook for the stock moving forward....

View All News

Announcement

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

02-Feb-2026 | Source : BSE

Transcript of the Investor/Analyst Earnings Call held on 27th January 2026: This is in continuation to our letter dated 27th January 2026 wherein we had informed regarding the audio link of the earnings call with analysts/investors for the quarter and nine months ended 31st December 2025.The transcript will be available on the Companys website.

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

02-Feb-2026 | Source : BSE

Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 Pursuant to Regulation 30 read with Schedule III (Part A) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we would like to inform you that the officials of the Company will be attending the Investor Conference as per the details provided in intimation.

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

02-Feb-2026 | Source : BSE

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."